A Phase 1, Randomized, Double-blind, Third-party Open, Placebo-controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single And/or Multiple Intravenous And/or Subcutaneous Doses Of Pf-06817024 In Healthy Subjects Who May Be Mildly Atopic, Subjects With Chronic Rhinosinusitis With Nasal Polyps, And Subjects With Moderate-severe Atopic Dermatitis

Trial Profile

A Phase 1, Randomized, Double-blind, Third-party Open, Placebo-controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single And/or Multiple Intravenous And/or Subcutaneous Doses Of Pf-06817024 In Healthy Subjects Who May Be Mildly Atopic, Subjects With Chronic Rhinosinusitis With Nasal Polyps, And Subjects With Moderate-severe Atopic Dermatitis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs PF 06817024 (Primary) ; PF 06817024
  • Indications Atopic dermatitis; Rhinosinusitis
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Nov 2017 Planned End Date changed from 3 Feb 2020 to 13 May 2020.
    • 08 Nov 2017 Planned primary completion date changed from 3 Feb 2020 to 13 May 2020.
    • 05 Oct 2017 Planned number of patients changed from 99 to 145.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top